Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients
In order to investigate the prognostic value of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), the blood cells from 98 MBC patients and 60 controls were evaluated by RT-PCR to detect the presence of markers EpCAM , CK19 , and hMAM . Peripheral blood was obtained from...
Gespeichert in:
| Veröffentlicht in: | Cell biochemistry and biophysics 2013-03, Vol.65 (2), p.263-273 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 273 |
|---|---|
| container_issue | 2 |
| container_start_page | 263 |
| container_title | Cell biochemistry and biophysics |
| container_volume | 65 |
| creator | Zhao, Shu Yang, Huike Zhang, Minghui Zhang, Dekai Liu, Yupeng Liu, Yan Song, Ying Zhang, Xiaosan Li, Hongbin Ma, Wenjie Zhang, Qingyuan |
| description | In order to investigate the prognostic value of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), the blood cells from 98 MBC patients and 60 controls were evaluated by RT-PCR to detect the presence of markers
EpCAM
,
CK19
, and
hMAM
. Peripheral blood was obtained from all patients with MBC before any systemic therapy. Immunofluorescence staining experiment was conducted on CTCs samples from 10 patients to investigate the coexpression of EpCAM, CK19, and hMAM. In addition, analyses were carried out for their correlation with patients’ clinicopathologic features.
EpCAM
+,
CK19
+, and
hMAM
+ cells were detected in 50 (51.0 %), 43 (43.9 %), and 68 (69.4 %) of the 98 patients, respectively. Triple-marker-positive CTCs were detected in 86 of 98 (87.8 %) patients with a significantly higher rate than the control group. Among the 98 patients, 12 (12.2 %) patients were negative for three genes, 34 (34.7 %) positive for one gene, 29 (29.6 %) positive for any two genes, and 23 (23.5 %) positive for all three genes. Compared to single-marker detection, the triple combined marker detection exhibited significantly higher rate. Furthermore, the specificity of triple combined markers of serial test was 100 %. The expression of three genes was significantly correlated with lymph node metastasis, high histological grade, and high levels of serum CA153 and CEA. Double-immunofluorescence labeling confirmed the presence of following CTCs phenotypes: CK19+/hMAM+, CK19+/hMAM−, CK19−/hMAM+, CK19+/EpCAM+, CK19−/EpCAM+, CK19+/EpCAM−, hMAM+/EpCAM+, and hMAM+/EpCAM−. After 2 years of follow-up, the presence of CTCs with triple-marker positive in peripheral blood was an independent risk factor for reduced progression-free survival (PFS) and overall survival (OS), and the presence of CTCs before any chemotherapy predicts poor OS and PFS in patients with MBC. |
| doi_str_mv | 10.1007/s12013-012-9426-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1289483263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2894825411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-26ba1ffc2d3f7b93b92b8989fea66287c1b44462216e2a903aea69d81675c67b3</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxiMEoqXwAFyQJS5FqsGeJI59XEz5Ixq1WoVz5DiTNiVxtrZz6OPwpnjZghASJ489v_nGM1-WveTsLWesehc4MJ5TxoGqAgSFR9kxL0tFGcj8cYqZLKniqjzKnoVwyxgAK4qn2RGAUiwX_Dj7oUdv18nE0V2TZp0XTzROUyCnutHhDfmAEW3EnnT3pPHjbkJaG_8dPTnf6U19RvRXrs6IcT25qTc12Tb0Sm9_3ZsbHD3Z4l58cSQuRE-jG62ZyOUa7TIjGR2pMZoQE2LJe48pJNo4m_Sv0hu6GJ5nTwYzBXzxcJ5k3z6eN_ozvbj89EVvLqjNK4gURGf4MFjo86HqVN4p6KSSakAjBMjK8q4oCgHABYJJ05uUUL3koiqtqLr8JDs96O78crdiiO08Bpt2YRwua2g5SFXIHESe0Nf_oLfL6l363Z6SgpdSFIniB8r6JQSPQ7vz42z8fctZu_evPfjXJv_avX8tpJpXD8prN2P_p-K3YQmAAxBSyl2j_6v1f1V_AlsdorY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1288615864</pqid></control><display><type>article</type><title>Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Zhao, Shu ; Yang, Huike ; Zhang, Minghui ; Zhang, Dekai ; Liu, Yupeng ; Liu, Yan ; Song, Ying ; Zhang, Xiaosan ; Li, Hongbin ; Ma, Wenjie ; Zhang, Qingyuan</creator><creatorcontrib>Zhao, Shu ; Yang, Huike ; Zhang, Minghui ; Zhang, Dekai ; Liu, Yupeng ; Liu, Yan ; Song, Ying ; Zhang, Xiaosan ; Li, Hongbin ; Ma, Wenjie ; Zhang, Qingyuan</creatorcontrib><description>In order to investigate the prognostic value of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), the blood cells from 98 MBC patients and 60 controls were evaluated by RT-PCR to detect the presence of markers
EpCAM
,
CK19
, and
hMAM
. Peripheral blood was obtained from all patients with MBC before any systemic therapy. Immunofluorescence staining experiment was conducted on CTCs samples from 10 patients to investigate the coexpression of EpCAM, CK19, and hMAM. In addition, analyses were carried out for their correlation with patients’ clinicopathologic features.
EpCAM
+,
CK19
+, and
hMAM
+ cells were detected in 50 (51.0 %), 43 (43.9 %), and 68 (69.4 %) of the 98 patients, respectively. Triple-marker-positive CTCs were detected in 86 of 98 (87.8 %) patients with a significantly higher rate than the control group. Among the 98 patients, 12 (12.2 %) patients were negative for three genes, 34 (34.7 %) positive for one gene, 29 (29.6 %) positive for any two genes, and 23 (23.5 %) positive for all three genes. Compared to single-marker detection, the triple combined marker detection exhibited significantly higher rate. Furthermore, the specificity of triple combined markers of serial test was 100 %. The expression of three genes was significantly correlated with lymph node metastasis, high histological grade, and high levels of serum CA153 and CEA. Double-immunofluorescence labeling confirmed the presence of following CTCs phenotypes: CK19+/hMAM+, CK19+/hMAM−, CK19−/hMAM+, CK19+/EpCAM+, CK19−/EpCAM+, CK19+/EpCAM−, hMAM+/EpCAM+, and hMAM+/EpCAM−. After 2 years of follow-up, the presence of CTCs with triple-marker positive in peripheral blood was an independent risk factor for reduced progression-free survival (PFS) and overall survival (OS), and the presence of CTCs before any chemotherapy predicts poor OS and PFS in patients with MBC.</description><identifier>ISSN: 1085-9195</identifier><identifier>EISSN: 1559-0283</identifier><identifier>DOI: 10.1007/s12013-012-9426-2</identifier><identifier>PMID: 22990361</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - genetics ; Antigens, Neoplasm - metabolism ; Biochemistry ; Biological and Medical Physics ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Biomedical and Life Sciences ; Biophysics ; Biotechnology ; Breast Neoplasms - blood ; Breast Neoplasms - diagnosis ; Breast Neoplasms - genetics ; Cell Adhesion Molecules - genetics ; Cell Adhesion Molecules - metabolism ; Cell Biology ; Clinical outcomes ; Disease-Free Survival ; DNA-Binding Proteins - genetics ; DNA-Binding Proteins - metabolism ; Epithelial Cell Adhesion Molecule ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Keratin-19 - genetics ; Keratin-19 - metabolism ; Life Sciences ; Lymphatic Metastasis ; Microscopy, Fluorescence ; Middle Aged ; Neoplastic Cells, Circulating - metabolism ; Pharmacology/Toxicology ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction ; Risk Factors ; Sensitivity and Specificity ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Translational Biomedical Research</subject><ispartof>Cell biochemistry and biophysics, 2013-03, Vol.65 (2), p.263-273</ispartof><rights>Springer Science+Business Media New York 2012</rights><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-26ba1ffc2d3f7b93b92b8989fea66287c1b44462216e2a903aea69d81675c67b3</citedby><cites>FETCH-LOGICAL-c372t-26ba1ffc2d3f7b93b92b8989fea66287c1b44462216e2a903aea69d81675c67b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12013-012-9426-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12013-012-9426-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22990361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Shu</creatorcontrib><creatorcontrib>Yang, Huike</creatorcontrib><creatorcontrib>Zhang, Minghui</creatorcontrib><creatorcontrib>Zhang, Dekai</creatorcontrib><creatorcontrib>Liu, Yupeng</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Song, Ying</creatorcontrib><creatorcontrib>Zhang, Xiaosan</creatorcontrib><creatorcontrib>Li, Hongbin</creatorcontrib><creatorcontrib>Ma, Wenjie</creatorcontrib><creatorcontrib>Zhang, Qingyuan</creatorcontrib><title>Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients</title><title>Cell biochemistry and biophysics</title><addtitle>Cell Biochem Biophys</addtitle><addtitle>Cell Biochem Biophys</addtitle><description>In order to investigate the prognostic value of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), the blood cells from 98 MBC patients and 60 controls were evaluated by RT-PCR to detect the presence of markers
EpCAM
,
CK19
, and
hMAM
. Peripheral blood was obtained from all patients with MBC before any systemic therapy. Immunofluorescence staining experiment was conducted on CTCs samples from 10 patients to investigate the coexpression of EpCAM, CK19, and hMAM. In addition, analyses were carried out for their correlation with patients’ clinicopathologic features.
EpCAM
+,
CK19
+, and
hMAM
+ cells were detected in 50 (51.0 %), 43 (43.9 %), and 68 (69.4 %) of the 98 patients, respectively. Triple-marker-positive CTCs were detected in 86 of 98 (87.8 %) patients with a significantly higher rate than the control group. Among the 98 patients, 12 (12.2 %) patients were negative for three genes, 34 (34.7 %) positive for one gene, 29 (29.6 %) positive for any two genes, and 23 (23.5 %) positive for all three genes. Compared to single-marker detection, the triple combined marker detection exhibited significantly higher rate. Furthermore, the specificity of triple combined markers of serial test was 100 %. The expression of three genes was significantly correlated with lymph node metastasis, high histological grade, and high levels of serum CA153 and CEA. Double-immunofluorescence labeling confirmed the presence of following CTCs phenotypes: CK19+/hMAM+, CK19+/hMAM−, CK19−/hMAM+, CK19+/EpCAM+, CK19−/EpCAM+, CK19+/EpCAM−, hMAM+/EpCAM+, and hMAM+/EpCAM−. After 2 years of follow-up, the presence of CTCs with triple-marker positive in peripheral blood was an independent risk factor for reduced progression-free survival (PFS) and overall survival (OS), and the presence of CTCs before any chemotherapy predicts poor OS and PFS in patients with MBC.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biochemistry</subject><subject>Biological and Medical Physics</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biophysics</subject><subject>Biotechnology</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - genetics</subject><subject>Cell Adhesion Molecules - genetics</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Cell Biology</subject><subject>Clinical outcomes</subject><subject>Disease-Free Survival</subject><subject>DNA-Binding Proteins - genetics</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Epithelial Cell Adhesion Molecule</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Keratin-19 - genetics</subject><subject>Keratin-19 - metabolism</subject><subject>Life Sciences</subject><subject>Lymphatic Metastasis</subject><subject>Microscopy, Fluorescence</subject><subject>Middle Aged</subject><subject>Neoplastic Cells, Circulating - metabolism</subject><subject>Pharmacology/Toxicology</subject><subject>Prognosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Translational Biomedical Research</subject><issn>1085-9195</issn><issn>1559-0283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kc9u1DAQxiMEoqXwAFyQJS5FqsGeJI59XEz5Ixq1WoVz5DiTNiVxtrZz6OPwpnjZghASJ489v_nGM1-WveTsLWesehc4MJ5TxoGqAgSFR9kxL0tFGcj8cYqZLKniqjzKnoVwyxgAK4qn2RGAUiwX_Dj7oUdv18nE0V2TZp0XTzROUyCnutHhDfmAEW3EnnT3pPHjbkJaG_8dPTnf6U19RvRXrs6IcT25qTc12Tb0Sm9_3ZsbHD3Z4l58cSQuRE-jG62ZyOUa7TIjGR2pMZoQE2LJe48pJNo4m_Sv0hu6GJ5nTwYzBXzxcJ5k3z6eN_ozvbj89EVvLqjNK4gURGf4MFjo86HqVN4p6KSSakAjBMjK8q4oCgHABYJJ05uUUL3koiqtqLr8JDs96O78crdiiO08Bpt2YRwua2g5SFXIHESe0Nf_oLfL6l363Z6SgpdSFIniB8r6JQSPQ7vz42z8fctZu_evPfjXJv_avX8tpJpXD8prN2P_p-K3YQmAAxBSyl2j_6v1f1V_AlsdorY</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Zhao, Shu</creator><creator>Yang, Huike</creator><creator>Zhang, Minghui</creator><creator>Zhang, Dekai</creator><creator>Liu, Yupeng</creator><creator>Liu, Yan</creator><creator>Song, Ying</creator><creator>Zhang, Xiaosan</creator><creator>Li, Hongbin</creator><creator>Ma, Wenjie</creator><creator>Zhang, Qingyuan</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20130301</creationdate><title>Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients</title><author>Zhao, Shu ; Yang, Huike ; Zhang, Minghui ; Zhang, Dekai ; Liu, Yupeng ; Liu, Yan ; Song, Ying ; Zhang, Xiaosan ; Li, Hongbin ; Ma, Wenjie ; Zhang, Qingyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-26ba1ffc2d3f7b93b92b8989fea66287c1b44462216e2a903aea69d81675c67b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biochemistry</topic><topic>Biological and Medical Physics</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biophysics</topic><topic>Biotechnology</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - genetics</topic><topic>Cell Adhesion Molecules - genetics</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Cell Biology</topic><topic>Clinical outcomes</topic><topic>Disease-Free Survival</topic><topic>DNA-Binding Proteins - genetics</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Epithelial Cell Adhesion Molecule</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Keratin-19 - genetics</topic><topic>Keratin-19 - metabolism</topic><topic>Life Sciences</topic><topic>Lymphatic Metastasis</topic><topic>Microscopy, Fluorescence</topic><topic>Middle Aged</topic><topic>Neoplastic Cells, Circulating - metabolism</topic><topic>Pharmacology/Toxicology</topic><topic>Prognosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Translational Biomedical Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Shu</creatorcontrib><creatorcontrib>Yang, Huike</creatorcontrib><creatorcontrib>Zhang, Minghui</creatorcontrib><creatorcontrib>Zhang, Dekai</creatorcontrib><creatorcontrib>Liu, Yupeng</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Song, Ying</creatorcontrib><creatorcontrib>Zhang, Xiaosan</creatorcontrib><creatorcontrib>Li, Hongbin</creatorcontrib><creatorcontrib>Ma, Wenjie</creatorcontrib><creatorcontrib>Zhang, Qingyuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cell biochemistry and biophysics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Shu</au><au>Yang, Huike</au><au>Zhang, Minghui</au><au>Zhang, Dekai</au><au>Liu, Yupeng</au><au>Liu, Yan</au><au>Song, Ying</au><au>Zhang, Xiaosan</au><au>Li, Hongbin</au><au>Ma, Wenjie</au><au>Zhang, Qingyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients</atitle><jtitle>Cell biochemistry and biophysics</jtitle><stitle>Cell Biochem Biophys</stitle><addtitle>Cell Biochem Biophys</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>65</volume><issue>2</issue><spage>263</spage><epage>273</epage><pages>263-273</pages><issn>1085-9195</issn><eissn>1559-0283</eissn><abstract>In order to investigate the prognostic value of circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC), the blood cells from 98 MBC patients and 60 controls were evaluated by RT-PCR to detect the presence of markers
EpCAM
,
CK19
, and
hMAM
. Peripheral blood was obtained from all patients with MBC before any systemic therapy. Immunofluorescence staining experiment was conducted on CTCs samples from 10 patients to investigate the coexpression of EpCAM, CK19, and hMAM. In addition, analyses were carried out for their correlation with patients’ clinicopathologic features.
EpCAM
+,
CK19
+, and
hMAM
+ cells were detected in 50 (51.0 %), 43 (43.9 %), and 68 (69.4 %) of the 98 patients, respectively. Triple-marker-positive CTCs were detected in 86 of 98 (87.8 %) patients with a significantly higher rate than the control group. Among the 98 patients, 12 (12.2 %) patients were negative for three genes, 34 (34.7 %) positive for one gene, 29 (29.6 %) positive for any two genes, and 23 (23.5 %) positive for all three genes. Compared to single-marker detection, the triple combined marker detection exhibited significantly higher rate. Furthermore, the specificity of triple combined markers of serial test was 100 %. The expression of three genes was significantly correlated with lymph node metastasis, high histological grade, and high levels of serum CA153 and CEA. Double-immunofluorescence labeling confirmed the presence of following CTCs phenotypes: CK19+/hMAM+, CK19+/hMAM−, CK19−/hMAM+, CK19+/EpCAM+, CK19−/EpCAM+, CK19+/EpCAM−, hMAM+/EpCAM+, and hMAM+/EpCAM−. After 2 years of follow-up, the presence of CTCs with triple-marker positive in peripheral blood was an independent risk factor for reduced progression-free survival (PFS) and overall survival (OS), and the presence of CTCs before any chemotherapy predicts poor OS and PFS in patients with MBC.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>22990361</pmid><doi>10.1007/s12013-012-9426-2</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1085-9195 |
| ispartof | Cell biochemistry and biophysics, 2013-03, Vol.65 (2), p.263-273 |
| issn | 1085-9195 1559-0283 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1289483263 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Antigens, Neoplasm - genetics Antigens, Neoplasm - metabolism Biochemistry Biological and Medical Physics Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biophysics Biotechnology Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - genetics Cell Adhesion Molecules - genetics Cell Adhesion Molecules - metabolism Cell Biology Clinical outcomes Disease-Free Survival DNA-Binding Proteins - genetics DNA-Binding Proteins - metabolism Epithelial Cell Adhesion Molecule Female Gene Expression Regulation, Neoplastic Humans Keratin-19 - genetics Keratin-19 - metabolism Life Sciences Lymphatic Metastasis Microscopy, Fluorescence Middle Aged Neoplastic Cells, Circulating - metabolism Pharmacology/Toxicology Prognosis Reverse Transcriptase Polymerase Chain Reaction Risk Factors Sensitivity and Specificity Transcription Factors - genetics Transcription Factors - metabolism Translational Biomedical Research |
| title | Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A38%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20Tumor%20Cells%20(CTCs)%20Detected%20by%20Triple-Marker%20EpCAM,%20CK19,%20and%20hMAM%20RT-PCR%20and%20Their%20Relation%20to%20Clinical%20Outcome%20in%20Metastatic%20Breast%20Cancer%20Patients&rft.jtitle=Cell%20biochemistry%20and%20biophysics&rft.au=Zhao,%20Shu&rft.date=2013-03-01&rft.volume=65&rft.issue=2&rft.spage=263&rft.epage=273&rft.pages=263-273&rft.issn=1085-9195&rft.eissn=1559-0283&rft_id=info:doi/10.1007/s12013-012-9426-2&rft_dat=%3Cproquest_cross%3E2894825411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1288615864&rft_id=info:pmid/22990361&rfr_iscdi=true |